Kaleido Biosciences Competitors

Kaleido Biosciences (NASDAQ:KLDO) and Connect Biopharma Holdings Limited American Depositary Shares (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares, as provided by MarketBeat.com.

Kaleido Biosciences presently has a consensus target price of $17.90, suggesting a potential upside of 194.41%. Connect Biopharma Holdings Limited American Depositary Shares has a consensus target price of $29.50, suggesting a potential upside of 72.72%. Given Kaleido Biosciences' higher probable upside, equities research analysts plainly believe Kaleido Biosciences is more favorable than Connect Biopharma Holdings Limited American Depositary Shares.

Institutional and Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares' revenue, earnings per share and valuation.

Summary

Kaleido Biosciences beats Connect Biopharma Holdings Limited American Depositary Shares on 4 of the 5 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Bolt Biotherapeutics, as provided by MarketBeat.

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Bolt Biotherapeutics has a consensus price target of $41.00, suggesting a potential upside of 68.86%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Bolt Biotherapeutics.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Bolt Biotherapeutics' revenue, earnings per share and valuation.

Summary

Kaleido Biosciences beats Bolt Biotherapeutics on 3 of the 4 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and 4D Molecular Therapeutics, as provided by MarketBeat.

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. 4D Molecular Therapeutics has a consensus price target of $45.50, suggesting a potential upside of 41.66%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than 4D Molecular Therapeutics.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and 4D Molecular Therapeutics' revenue, earnings per share and valuation.

Summary

Kaleido Biosciences beats 4D Molecular Therapeutics on 4 of the 5 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Gracell Biotechnologies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Gracell Biotechnologies, as provided by MarketBeat.

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Gracell Biotechnologies has a consensus price target of $34.50, suggesting a potential upside of 179.58%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Gracell Biotechnologies.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Gracell Biotechnologies' revenue, earnings per share and valuation.

Summary

Kaleido Biosciences beats Gracell Biotechnologies on 3 of the 4 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Pharvaris B.V. (NASDAQ:PHVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Pharvaris B.V.'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Pharvaris B.V., as provided by MarketBeat.

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Pharvaris B.V. has a consensus price target of $47.50, suggesting a potential upside of 104.65%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Pharvaris B.V..

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Pharvaris B.V.'s revenue, earnings per share and valuation.

Summary

Kaleido Biosciences beats Pharvaris B.V. on 4 of the 5 factors compared between the two stocks.

Pharming Group (NASDAQ:PHAR) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Pharming Group and Kaleido Biosciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Pharming Group and Kaleido Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and target prices for Pharming Group and Kaleido Biosciences, as reported by MarketBeat.com.

Kaleido Biosciences has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Given Kaleido Biosciences' higher probable upside, analysts plainly believe Kaleido Biosciences is more favorable than Pharming Group.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kaleido Biosciences beats Pharming Group on 4 of the 4 factors compared between the two stocks.